Breast Cancer

Investigational NDA to be submitted for breast and liver cancer drug

Published in Medical Letter on the CDC and FDA, February 29th, 2004

Provectus Pharmaceuticals (PVCT) is preparing an Investigational New Drug (IND) application for Provecta, a drug therapy intended for breast and liver cancer.

If the U.S. Food and Drug Administration accepts the application, Provectus hopes to begin enrolling patients by mid-2004.

Provectus has successfully completed a full range of preclinical studies in laboratory models. Additionally, Provecta has been used to treat a number of spontaneous tumors in veterinary subjects.

"We are extremely pleased to begin moving this drug through the regulatory process in a manner which we hope will result in Fast Track consideration by the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-02-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry